GLP-1 Receptor Agonists

This content was updated in October 2020 and will be valid for one year.

Interactive case study

Continue to practice your decision-making when intensifying treatment beyond triple therapy. Featuring local commentary from France, Spain and Italy.

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.

This content was updated in October 2020 and will be valid for one year.

eLearning module

A comprehensive overview of GLP-1 receptor agonists, including mechanism of action, multifactorial effects and how to predict response to their use in type 2 diabetes.

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.

This content was updated in October 2020 and will be valid for one year.

Digital symposium

eLearning module

A summary of guideline recommendations in the use of GLP-1 analogues, including how to help patients manage gastrointestinal side effects.

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.

This content was updated in October 2020 and will be valid for one year.

eLearning module

A comprehensive summary of relevant data across GLP-1RAs, SGLT2 inhibitors and DPP-4 inhibitors, complete with guidance on how to select between these.

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.

This content was updated in October 2020 and will be valid for one year.

eLearning module

A review of data surrounding once-weekly GLP-1 receptor agonists, including clinical trial data and how these apply to the real world.

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.

This content was updated in October 2020 and will be valid for one year.

eLearning module

A summary of formulations, mechanisms of action and clinical trial data associated with alternative approaches to GLP-1 agonism. This includes oral semaglutide, implantable exenatide, and dual agonists (e.g. tirzepatide)

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.